Inogen Inc (NASDAQ:INGN) CFO Alison Bauerlein sold 3,192 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $125.41, for a total value of $400,308.72. Following the transaction, the chief financial officer now directly owns 8,808 shares of the company’s stock, valued at $1,104,611.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Alison Bauerlein also recently made the following trade(s):
- On Friday, February 16th, Alison Bauerlein sold 8,808 shares of Inogen stock. The shares were sold at an average price of $125.03, for a total value of $1,101,264.24.
- On Wednesday, February 14th, Alison Bauerlein sold 9,737 shares of Inogen stock. The shares were sold at an average price of $120.05, for a total value of $1,168,926.85.
- On Friday, February 9th, Alison Bauerlein sold 11,718 shares of Inogen stock. The shares were sold at an average price of $115.87, for a total value of $1,357,764.66.
- On Monday, February 12th, Alison Bauerlein sold 27,630 shares of Inogen stock. The shares were sold at an average price of $116.46, for a total value of $3,217,789.80.
Shares of Inogen Inc (NASDAQ:INGN) opened at $129.36 on Thursday. Inogen Inc has a 52-week low of $67.34 and a 52-week high of $132.68. The stock has a market capitalization of $2,647.20, a P/E ratio of 103.12, a PEG ratio of 4.13 and a beta of 1.02.
Several institutional investors and hedge funds have recently added to or reduced their stakes in INGN. BlackRock Inc. lifted its position in shares of Inogen by 4.0% in the fourth quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock valued at $274,662,000 after buying an additional 87,737 shares during the last quarter. Rock Springs Capital Management LP acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $9,526,000. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $8,858,000. Prudential Financial Inc. lifted its position in shares of Inogen by 78.2% in the third quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock valued at $11,801,000 after buying an additional 54,467 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $5,874,000.
INGN has been the subject of several recent research reports. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Needham & Company LLC raised their price objective on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a research report on Thursday, November 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $120.00 price objective (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Inogen currently has a consensus rating of “Buy” and an average price target of $103.71.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/alison-bauerlein-sells-3192-shares-of-inogen-inc-ingn-stock.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.